A GA microsatellite in the Fli1 promoter modulates gene expression and is associated with systemic lupus erythematosus patients without nephritis

Erin E Morris¹, May Y Amria¹, Emily Kistner-Griffin², John L Svenson¹, Diane L Kamen¹, Gary S Gilkeson¹, Tamara K Nowling¹*

Abstract

Introduction: The transcription factor Fli1 is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Recently, a GAₙ polymorphic microsatellite was characterized in the mouse Fli1 promoter that modulates promoter activity and is truncated in two lupus mouse models compared to non-autoimmune prone mice. In this work, we characterize a homologous GAₙ microsatellite in the human Fli1 promoter. The purpose of this study is to determine the effect of the microsatellite length on Fli1 promoter activity in vitro and to determine if the length of the GAₙ microsatellite is associated with SLE and/or specific disease characteristics.

Methods: Constructs with variable lengths of the GAₙ microsatellite in the Fli1 promoter were generated and analyzed in promoter/reporter (P/R) assays in a human T cell line. Using three SLE patient cohorts and matched controls, microsatellite length was measured and association with the presence of disease and the occurrence of specific disease manifestations was assessed.

Results: P/R assays demonstrated that the presence of a shorter microsatellite resulted in higher Fli1 promoter activity. A significant association was observed in the lupus cohort SLE in Gullah Health (SLEIGH) between the GA₂₆ base pair allele and absence of nephritis.

Conclusions: This study demonstrates that a GAₙ microsatellite in the human Fli1 promoter is highly polymorphic. The length of the microsatellite is inversely correlated to Fli1 promoter activity in a human T cell line. Although no association between microsatellite length and lupus was observed, an association between a specific microsatellite length and patients without nephritis in the SLEIGH cohort was observed.

Introduction

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of autoantibodies, formation of immune complexes and subsequent deposition in target tissues with resultant local inflammation and organ damage [1]. Nearly every organ system can be involved in lupus with the most prominent being the kidneys, joints, skin and brain [1]. The major determinant of morbidity and mortality is renal involvement, although infection and cardiovascular disease are leading causes of death. The American College of Rheumatology outlines the most common disease outcomes of SLE in the 1997 revised classification criteria including arthritis, serositis, nephritis, immune-mediated cytopenias, and lupus-specific autoantibody positivity. Commonly, the course of disease will include periods of remission and flares and the disease presentation is heterogeneous among patients making SLE a difficult disease to characterize, diagnose, and study. Similar to most autoimmune diseases, lupus is believed to result from an environmental event triggering disease in a genetically susceptible individual.
Increasing evidence suggests that dysregulation of the transcription factor Fli1 contributes to the pathogenesis of lupus. Fli1 is a member of the Ets family of transcription factors and is preferentially expressed in endothelial and hematopoietic cell lineages. Levels of expression are linked to the pathogenesis of lupus. During lymphoid development, Fli1 is highly expressed in immune cells including mature B cells, pre-T cells, and resting, mature T cells [2]. Over-expression of Fli1 in peripheral blood mononuclear cells (PBMCs) in lupus patients is correlated with disease activity [3]. Fli1 is over-expressed in several lupus mouse models including T cells of NZB/NZW fl mice and spleen of MRL/lpr mice [3,4]. Transgenic global over-expression of Fli1 in healthy, non-autoimmune prone mice results in a lupus-like phenotype with the presence of autoreactive lymphocytes, autoantibodies and the development of immune complex mediated kidney disease [5]. Conversely, reduction of Fli1 levels by 50% in MRL/lpr and NZM2410 lupus-prone mice improved the disease phenotypes in these models by decreasing autoantibody production and kidney disease and significantly prolonging survival [4,6]. This evidence demonstrates that expression levels of Fli1 in lupus affect disease phenotype.

We demonstrated previously that a polymorphic microsatellite consisting of GA repeats within the proximal promoter of the mouse Fli1 gene is shorter in the MRL/lpr and NZM2410 lupus mouse models compared to non-autoimmune prone BALB/c and C57BL/6 mice [7]. Promoter/reporter (P/R) assays demonstrated that in vitro activity of the mouse Fli1 promoter in a T cell line was inversely correlated with microsatellite length. The murine and human Fli1 promoters are highly homologous with 88% homology in the proximal promoter region, including the GA microsatellite [8]. Together, these studies suggested that a shorter microsatellite in the Fli1 promoter may contribute to over-expression of Fli1 and to the pathogenesis of lupus. Using clinical data and genomic DNA specimens from SLE patients and controls, we demonstrate that the human microsatellite shows a similar inverse correlation between length and promoter activity in a human T cell line and that a microsatellite length of GA26 is significantly more prevalent in SLE patients without nephritis and tended to be more prevalent in SLE patients with serositis.

Materials and methods

Plasmid constructs
The promoter/reporter (P/R) constructs containing the -502 to -37 region of the human Fli1 gene were generated from genomic DNA isolated from control subjects in the Carolina Lupus Study as described previously [8]. The -502/-37 P/R constructs analyzed were identical except for the difference in microsatellite lengths; 28, 24, 16 or 13 GA repeats. Two clones for each of the microsatellite lengths were generated and tested. All constructs were confirmed by direct sequencing.

Transfections
pGL3 hFli1-502/-37 P/R constructs were transfected into the Jurkat human T cell line using Fugene (Pierce, Rockford, IL USA) following the manufacturer’s directions. A Renilla luciferase construct was co-transfected to normalize for transfection efficiency. Cells were harvested 24 hours after transfection and cell lysates were analyzed for luciferase expression using the dual luciferase detection kit (Promega, Madison, WI USA) and quantified using a luminometer. Promoter activity as a measure of luciferase expression was compared to the pGL3 Basic empty vector. Transfections were performed at least three times in duplicate with two different clones and averaged.

Cells
The Jurkat human T cell line was maintained in RPMI 1640 with 10% fetal bovine serum and antibiotics at 37°C and 5% humidity. Cells were passaged the day prior to transfection.

Microsatellite fragment length measurements
The microsatellite containing region of the Fli1 proximal promoter was amplified from genomic DNA from subjects in the Carolina Lupus study (CLU), SLE in Gullah Health study (SLEIGH) and the MUSC Lupus Clinic study (Clinic) using the following primers: upstream primer, hGA2Up, 5’-/56-FAM/ATGTGTCTGGGCGATCTCTC-3’, contains a FAM fluorescent tag; and downstream primer, GADn, 5’-GCTAATTGTTGGAAATGACT-3’. The amplified, FAM-tagged PCR products were sent to the DNA Facility at Iowa State University (Ames, IA, USA) for high throughput genotyping analysis using the Applied Biosystems 3100 Genetic Analyzer (Carlsbad, CA, USA) and size marker. Several samples, including those that were used to generate the P/R constructs, were run across multiple plates to ensure consistent amplification and sizing across plates and over half of the samples were run twice. The raw sizing data were visually analyzed for peak quality followed by analysis and binning using the GeneMapper software (Applied Biosystems, Carlsbad, CA, USA). Direct sequencing of 32 of the amplified products of various lengths demonstrated that the differences in amplified product sizes were due to the length of the microsatellite and not to other sequence changes.

Subjects
This study utilized subject data from three lupus cohorts. Genomic DNA was isolated from peripheral
blood samples obtained from the study cohorts taken upon receiving informed consent and in compliance with the Institutional Review Board for Human Studies. All aspects of this study were conducted according to the Helsinki Declaration. The Carolina Lupus (CLU) cohort is a case-control study investigating genetic and environmental factors predisposing individuals to SLE [9]. Patients enrolled in the CLU study were recruited through university and community rheumatology in eastern North Carolina and South Carolina. Patients met at least 4 of the 11 revised American College of Rheumatology classification criteria for SLE [10,11]. All patients were diagnosed with SLE between 1 January 1995 and 1 July 1999 and were enrolled in the CLU study within one year of diagnosis. Matched control subjects were recruited from state driver’s license registries. At the time of enrollment, blood samples were taken from the study subjects for the extraction of genomic DNA.

The Systemic Lupus Erythematosus in Gullah Health (SLEIGH) study includes African American lupus patients and controls living on the Sea Islands of the South Carolina and Georgia coasts [12]. SLEIGH subjects represent a unique genetic group with a low percent admixture of non-African genes. Subjects enrolled in the SLEIGH study were self-identified as a member of the African American Gullah community with no known ancestors that were not of Gullah lineage. Patients in SLEIGH met at least 4 of the 11 American College of Rheumatology classification criteria for SLE [10,11]. Patients were identified as multiplex if the diagnosis of SLE could be documented in one or more family members. Population controls in SLEIGH used for our analyses had no known family history of SLE or other autoimmune disease and were matched on age and gender to patient cases. Blood samples were taken from the study subjects at the time of enrollment for extraction of genomic DNA.

Caucasian and African American lupus patients from the MUSC clinic that met 4 of the 11 American College of Rheumatology classification criteria for SLE were included for data collection. Blood samples were taken for extraction of genomic DNA.

The clinic patients were included with the CLU study for analyses. Separate analyses were performed on the Caucasian and African American populations in order to avoid possible confounders due to population stratification. Initial analyses for the SLEIGH study data considered only patients not from multiplex families. Additional analyses were performed on the SLEIGH study data to include one multiplex patient chosen at random from each multiplex family. Within each cohort, three statistical testing approaches were considered.

**Statistics**

P/R assay data were analyzed by the Student’s t-test to identify statistically significant differences. To begin analyses of the patient cohort data, hypothesis-generating genotype tests were considered by dichotomizing into short/long alleles and using 2-df Fisher’s exact tests (or chi-squared tests where the counts of genotypes were above five for each possible genotype) to test for association with disease between cases and controls or individual disease characteristics within cases. Next, average allele length was compared between cases and controls using a two-sample t-test. Lastly, due to the large number of alleles observed, the CLUMP program was used to compare each allele to all the other possible alleles. The CLUMP program, described by Sham and Curtis [13], allows testing each allele frequency against all other allele frequencies, using a chi-squared test statistic. Statistical analyses were performed separately on patients from the SLEIGH study while patients in the CLU and MUSC clinic cohorts were analyzed together.

**Results**

A GA\textsubscript{n} dinucleotide repeat in the proximal promoter of the human Fli1 gene modulates in vitro promoter activity in T cells

A polymorphic GA\textsubscript{n} dinucleotide microsatellite is present in the proximal region of the human Fli1 promoter 271 base pairs upstream (-271) from the start site of translation (Figure 1A, B). The location of this GA\textsubscript{n} repeat is homologous to the polymorphic microsatellite we recently analyzed in the mouse Fli1 promoter [7]. In our previous study, deletion analyses of the human Fli1 promoter demonstrated that the microsatellite is not required for full promoter activity in a T cell line [8]. However, the microsatellite was demonstrated to modulate the activity of the mouse promoter in T cells such that the shorter the microsatellite the greater the promoter activity [7].

To determine if there is a similar inverse correlation between microsatellite length and promoter activity with the human Fli1 promoter, P/R constructs containing microsatellites of 28, 24, 16, and 13 GA repeats were transfected into the Jurkat human T cell line. The pGL3 construct containing 13 GA (GA\textsubscript{13}) repeats resulted in the highest level of Fli1 promoter activity (Figure 1C). Promoter activity decreased as microsatellite length increased with a statistically significant difference between the longest (GA\textsubscript{28}) and the shortest (GA\textsubscript{13}) alleles \((P < 0.001)\). This demonstrates that relative Fli1 promoter activity is inversely correlated with the number of GA repeats in this human T cell line similar to our previous study of the mouse Fli1 promoter [7].
In a previous study, expression of the Fli1 gene was shown to be elevated in T cells from SLE patients compared to unaffected control subjects [3]. Based on our results demonstrating that the length of the microsatellite is inversely correlated to Fli1 promoter activity and that a shorter microsatellite is present in lupus-prone mouse strains [7], we sought to determine whether the length of the microsatellite is associated with SLE. The microsatellite-containing region of the Fli1 promoter was amplified and length measured in the Carolina Lupus (CLU) study cohort, MUSC Lupus Clinic (Clinic) study cohort and the SLEIGH study cohort. Demographics are presented in Table 1. The CLU and Clinic cohorts were analyzed together and include 197 SLE patients and 162 unaffected controls. The SLEIGH cohort includes 154 patients and 97 unaffected controls and for statistical analyses, the cohort data was divided into two groups that either excluded multiplex families or included one randomly selected patient from each multiplex family.

Interestingly, following genotyping of these cohorts we observed over 20 different alleles with a range of GA repeats from 13 to 39 within these populations, indicating that this microsatellite is highly polymorphic in humans. Allele distributions for each cohort are presented in Table 1. The CLU and Clinic cohorts were analyzed together and include 197 SLE patients and 162 unaffected controls. The SLEIGH cohort includes 154 patients and 97 unaffected controls and for statistical analyses, the cohort data was divided into two groups that either excluded multiplex families or included one randomly selected patient from each multiplex family.

Distribution of microsatellite length in patients and control subjects

In a previous study, expression of the Fli1 gene was shown to be elevated in T cells from SLE patients compared to unaffected control subjects [3]. Based on our results demonstrating that the length of the microsatellite is inversely correlated to Fli1 promoter activity and that a shorter microsatellite is present in lupus-prone mouse strains [7], we sought to determine whether the length of the microsatellite is associated with SLE. The microsatellite-containing region of the Fli1 promoter was amplified and length measured in the Carolina Lupus (CLU) study cohort, MUSC Lupus Clinic (Clinic) study cohort and the SLEIGH study cohort. Demographics are presented in Table 1. The CLU and Clinic cohorts were analyzed together and include 197 SLE patients and 162 unaffected controls. The SLEIGH cohort includes 154 patients and 97 unaffected controls and for statistical analyses, the cohort data was divided into two groups that either excluded multiplex families or included one randomly selected patient from each multiplex family.
microsatellite is associated with disease. Next, we compared average microsatellite length between cases and controls. No association was observed with either of these analyses (data not shown).

We performed additional analyses to explore other phenotype-genotype associations that were not initially hypothesized, specifically the possibility that a particular length may be associated with disease or a disease phenotype. Analyses of length in cases and controls in the CLU cohort were separated into Caucasians (Figure 2A) and African Americans due to concerns of population stratification (Figure 2B). In general, the distribution of alleles was similar in cases and controls. These results indicate no significant differences in the overall

| Table 1 Demographics of the study cohorts |
|-----------------------------------------|
| Control Subjects | Age Range (Median Age) | Patient Subjects | Age Range (Median Age) |
|------------------|------------------------|------------------|------------------------|
| CLU/MUSC Clinic Caucasians | 110 | 18-75 (39) | 62 | 18-51 (36) |
| CLU/MUSC Clinic African Americans | 52 | 16-61 (33) | 135 | 15-54 (37) |
| SLEIGH Without multiplex patients | 97 | 11-74 (42) | 123 | 10-69 (37) |
| SLEIGH With multiplex patients | 97 | 11-74 (42) | 154 | 10-70 (39) |

The number of patients and controls and the median age ranges for the Carolina Lupus (CLU) study, Medical University of South Carolina (MUSC) clinic, and System Lupus Erythematosus in Gullah Health (SLEIGH) study participants.

Figure 2 Distribution of the GA$_n$ microsatellite allele in patient and control subjects of the CLU and SLEIGH cohorts. A. CLU Caucasian subjects. B. CLU African American subjects. C. African American patient population of the CLU cohort divided with respect to serositis occurrence. D. SLEIGH subjects excluding multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). E. SLEIGH subjects including multiplex patients (not shown on graph is one patient with an allele of 267 base pairs). F. SLEIGH patient population divided with respect to nephritis occurrence. *P < 0.05. All n values are representative of the number of patients, each patient having two alleles.
distribution of microsatellite length between SLE patients and unaffected controls in the CLU cohort regardless of ethnicity. The same analyses were performed with the SLEIGH cohort data. As in the CLU cohort, the overall distribution was similar between cases and controls whether the multiplex patients were excluded (Figure 2D) or included (Figure 2E). These results demonstrate no significant differences in the overall distribution of microsatellite length between SLE patients and unaffected controls in the SLEIGH cohort regardless of inclusion of multiplex patients.

Assessment of microsatellite length and lupus disease characteristics
To determine whether microsatellite length is associated with specific disease characteristics, microsatellite length was analyzed within the patient population of the CLU and SLEIGH cohorts. Analyses conducted include microsatellite length and occurrence of arthritis, nephritis, immune-mediated cytopenias, and lupus-specific autoantibody positivity. These disease characteristics were defined using the 1997 revised American College of Rheumatology SLE classification criteria [11]. The disease characteristic could have occurred at any point in the patient’s history, however, must be attributable to lupus. As with allele distribution analysis, no significant associations were observed in analyses of short and long alleles or average allele length with disease phenotypes (data not shown).

We then analyzed the occurrence of specific allele lengths with disease phenotypes. No significant associations were observed between microsatellite length and arthritis, cytopenias, or lupus-specific autoantibody positivity in the CLU Caucasian, CLU African American or SLEIGH populations (data not shown). Analyses of allele length with nephritis in the SLEIGH cohort, excluding multiplex patients, identified the 241 bp allele (GA26) as being more prevalent in patients that did not develop nephritis (Figure 2F). This difference was statistically significant after adjusting for multiple comparisons ($P < 0.05$) (Table 2). These results suggest that the 241 bp allele may be protective against the development of nephritis in SLE patients regardless of ethnicity. The same analyses were performed with the SLEIGH cohort data. As in the CLU cohort, the overall distribution was similar between cases and controls whether the multiplex patients were excluded (Figure 2D) or included (Figure 2E). These results demonstrate no significant differences in the overall distribution of microsatellite length between SLE patients and unaffected controls in the SLEIGH cohort regardless of inclusion of multiplex patients.

Table 2 Summary of results

| Alleles associated with patients | CLU Caucasian (n = 62) | AA (n = 135) | Without Multiplex (n = 123) | With Multiplex (n = 154) |
|---------------------------------|-----------------------|-------------|---------------------------|-------------------------|
| With Serositis                  | none                  | 239/241     | 239                       | 239                     |
| Without Nephritis               | none                  | none        | 241 (p < 0.05)            | 241                     |

Summary of results for the Carolina Lupus (CLU) study African American (AA) and Caucasian participants and for the Systemic Lupus Erythematosus in Gullah Health (SLEIGH) participants.

Discussion
We previously demonstrated that a polymorphic GA$_n$ microsatellite in the mouse Fli1 promoter modulates promoter activity in a T cell line and is evolutionarily conserved [7]. Although the GA$_n$ microsatellite in the mouse and human promoters is not required for promoter activity in vitro [7,8], varying the length of the microsatellite in the mouse promoter modulated promoter activity in T cells with the length of the microsatellite being inversely proportional to promoter activity [7]. Here we determined that the in vitro activity of the human Fli1 promoter also decreased as the number of GA repeats in the microsatellite increased (Figure 1C). The inverse relationship between microsatellite length and Fli1 promoter activity observed in mouse and human suggests a possible functional role of the GA$_n$ microsatellite in the regulation of Fli1 expression.

Microsatellites occur at high frequency in the protein coding and non-coding regions of the human genome, which has raised many questions about their function in normal development and disease states [14]. Although there are many examples in the literature of the ability of microsatellites to affect expression of genes (including EGFR, estrogen receptor β, Kv1.5, nucleolin, acetyl CoA carboxylase, heme oxygenase 1, matrix metalloproteinase 9, Cyr61, heat shock genes, collagen Iα2, and Pax6 [15-26]), the mechanisms involved are not entirely understood. Microsatellites are thought to function primarily by altering chromatin structure. Specifically, properties of GA microsatellites include the ability to adopt...
H-form DNA and bind GAGA factor. The H-DNA conformation includes both single- and triple-stranded regions that are DNase I-hypersensitive [27] and may provide an open chromatin configuration that allows binding of transcription factors to neighboring regulatory elements [28,29]. GAGA factor is a protein identified in Drosophila and its binding to GA-rich sequences in promoters can repress or activate transcription through effects on nucleosomes [30-33]. Recently, the vertebrate homolog of GAGA factor, th-POK, was identified and demonstrated to bind GA-rich sequences [34]. Additionally, GA-rich sequences are thought to play a role as enhancer-blocking or insulator elements [35]. The Fli1 GA microsatellite was demonstrated previously to be sensitive to nuclease S1 digestion and shown to form H-DNA in vitro [36,37]. Our in vitro experiments with both the mouse and human promoters support a role of the microsatellite in dampening promoter activity as length increases but not in complete repression of activity. How this microsatellite functions in vivo remains to be determined.

Previous results demonstrated that Fli1 expression is increased in mouse models of lupus [3,4] and in T cells of SLE patients [3] compared to unaffected controls. Interestingly, globally decreasing Fli1 levels by 50% in two different lupus mouse models resulted in significantly improved disease, most notably improved nephritis, accompanied by significantly prolonged survival [4,6]. Furthermore, it was demonstrated that reducing Fli1 levels by 50% in hematopoietic cells in a lupus mouse model also resulted in improved disease and survival [38]. Together these studies demonstrated that modulating Fli1 levels plays an important role in the progression of lupus. Based on these observations and our P/R results demonstrating that the length of the microsatellite modulates Fli1 expression, we hypothesized that a shorter microsatellite in the Fli1 promoter may lead to over-expression of Fli1 and thus may be associated with lupus or with specific disease phenotypes such as nephritis. The association of microsatellites with the occurrence of several diseases including SLE, rheumatoid arthritis, lung fibrosis, epithelial ovarian cancer, thyroid cancer, acute pancreatitis, breast cancer, and multiple neurological diseases has been reported [39-48].

We expected the microsatellite to be polymorphic in the human population; however, we were surprised to observe more than 20 different alleles spanning 13 to 39 GA repeats in the populations tested, including the highly genetically related SLEIGH population. The highly polymorphic nature of this microsatellite is interesting and prompted multiple analyses to explore all possible phenotype-genotype associations. Although the GA\textsubscript{n} microsatellite length had an effect on Fli1 promoter activity in vitro, no association was identified between microsatellite allele length and the occurrence of SLE in the SLEIGH and CLU cohorts. The pathogenesis of SLE is complex and it is likely that the disease results from alterations in the expression of multiple target genes. Thus, Fli1 may contribute to the progression of disease but we believe it is more likely to be associated with a specific disease characteristic.

To determine if GA microsatellite length is associated with specific aspects of SLE we compared the presence of lupus-specific characteristics with microsatellite length. No association was observed between microsatellite length and arthritis, cytopenia or lupus specific autoantibodies. To our knowledge, it is unknown whether Fli1 plays a role in the development of arthritis or cytopenia in lupus, although it was demonstrated that reducing Fli1 levels in a lupus mouse model had no effect on total B cell or T cell numbers [4]. Therefore, it is not unexpected that no association between the Fli1 microsatellite and arthritis or cytopenia was observed. Based on results in lupus mouse models in which reducing Fli1 levels resulted in decreased autoantibody levels [4,6], we expected to observe an association of the Fli1 microsatellite with autoantibody production. However, the effect of Fli1 on autoantibody levels appears to be secondary to effects on B cell activation [4], which may account for the apparent lack of association of the Fli1 microsatellite with autoantibodies in our study.

The 241 bp allele (GA\textsubscript{26}), was significantly associated with SLE patients that did not have nephritis in the SLEIGH cohort (Figure 2F and Table 2). Alleles of 239 and 241 bp, 25 and 26 GA repeats respectively, were more prevalent, although not significantly, in African American CLU patients with serositis (Figure 2C and Table 2). In vitro constructs in this long size range (23 to 28 repeats) exhibited weaker activation of the Fli1 promoter in P/R assays (Figure 1C), suggesting that lower Fli1 expression may be protective against nephritis and contribute to serositis. In lupus mouse models in which Fli1 levels were reduced globally or specifically in hematopoietic cells, nephritis was improved [4,6,38]. Conversely, expression of Fli1 in mouse endothelial cells controls vascular maturation and is required to maintain vascular integrity [49]. We speculate that a reduction in Fli1 promoter activity and, hence, expression may disrupt endothelial cell function in lupus patients and contribute to exaggerated serositis.

These findings support previous hypotheses that the effects of Fli1 expression in different cell types are variable and aberrant expression of Fli1 can contribute to the development of disease. For example, in scleroderma, reduced expression of Fli1 in skin fibroblasts and endothelial cells is implicated in the fibrotic and vascular components of the phenotype [49], while in lupus...
elevated expression of Fli1 in mononuclear cells is thought to contribute to the disease phenotype [3]. It is conceivable that the 241 bp allele representing a microsatellite of 26 GA repeats may delineate a threshold length of the microsatellite. Individuals with a Fli1 GA_n microsatellite at or above the threshold may have lower levels of Fli1 expression in their lymphocytes, which would be protective against developing lupus nephritis while individuals with a Fli1 GA_n microsatellite at or above the threshold may have lower expression levels of Fli1 in their endothelial cells, which may contribute to serositis. However, we tested all dichotomies of short/long alleles and didn’t observe significant differences, suggesting that increased and decreased expression of Fli1 may be modulated by a specific length of the GA microsatellite.

Conclusions
In this work, we characterized a highly polymorphic microsatellite of GA repeats in the human Fli1 promoter. Variable lengths of the GA_n microsatellite modulated Fli1 promoter activity in vitro in a human T cell line such that the shorter the microsatellite the greater the promoter activity. Although aberrant expression of Fli1 in PBMCs was observed previously in SLE patients [3], specific association between microsatellite length and SLE was not observed in this study. However, the GA26 microsatellite length was specifically associated with patients that did not have nephritis and tended to be more prevalent in African American patients with serositis. Due to the highly polymorphic nature of this microsatellite, a greater number of additional subjects in these cohorts would be required to increase the statistical power in order to determine significant associations for each allele and/or genotype, especially within the shortest and longest alleles, which appear to be relatively rare. The expression of Fli1 in different cell types may mediate pathological effects that contribute to the multifaceted role of Fli1 in SLE. A more precise understanding of how this microsatellite functions to modulate Fli1 expression in different cell types would be beneficial in determining whether this microsatellite may serve as therapeutic marker in lupus. Future studies are aimed at determining whether the length of the Fli1 GA_n microsatellite correlates with Fli1 expression levels in primary human cells and how the GA microsatellite precisely functions to modulate expression.

Abbreviations
CLU: Carolina Lupus Study; CTCF: CCCTC binding factor; PBMCs: peripheral blood mononuclear cell; P/R: promoter/reporter; SLE: Systemic Lupus Erythematosus; SLEIGH: Systemic Lupus Erythematosus in Guillian Health.

Acknowledgements
This work was supported by a grant from the Alliance for Lupus Research awarded to TKN and in part by NIH grant AR053376 awarded to TKN.

Author details
1. Division of Rheumatology, Department of Medicine, Medical University of South Carolina, 96 Jonathon Lucas St., Charleston, SC 29425, USA.
2. Department of Biostatistics and Epidemiology, Medical University of South Carolina, 86 Jonathon Lucas St., Charleston, SC 29425, USA.

Authors’ contributions
EEM drafted the manuscript and contributed to organizing and analyzing data. MYA performed the real-time PCR experimentation, P/R transfections and data collection. EKG performed the statistical analyses of the data. JLS participated in the data analyses and writing of the manuscript. DLK and GSG provided the qDNA samples and demographic information for the cohorts and contributed to the data analyses. TKN conceived of the study, designed the experiments and contributed to all aspects of the data collection and analyses and drafting and editing of the manuscript. All authors read and approved of the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 6 April 2010 Revised: 7 October 2010 Accepted: 18 November 2010 Published: 18 November 2010

References
1. Oates JC, Gilkeson GS: Mediators of injury in lupus nephritis, Curr Opin Rheumatol 2002, 14:498-503.
2. Anderson MK, Hernandez-Hoyos G, Diamond RA, Rothenberg EV: Precise developmental regulation of Ets family transcription factors during specification and commitment to the T cell lineage. Development 1999, 126:3131-3148.
3. Georgiou P, Markoulakou KG, Green JE, Dantis P, Romano-Spica V, Kottaridas S, Lautenberger JA, Watson DK, Papas TS, Fischinger PJ, Bhat NK: Expression of ets family genes of systemic lupus erythematosus and Sjogren’s syndrome. International Journal of Oncology 1996, 9:9-18.
4. Zhang XX, Gallant S, Molano I, Moussa OM, Ruiz P, Spyropoulos DD, Watson DK, Gilkeson G: Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol 2004, 173:6481-6489.
5. Zhang L, Eddy A, Teng YT, Fritzler M, Kluppel M, Melet F, Bernstein A: An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes. Molecular and Cellular Biology 1995, 15:6961-6970.
6. Mathenia J, R-C E, Williams S, Molano I, Ruiz P, Watson D, Gilkeson G, Zhang X: Impact of Fli1-1 transcription factor on autoantibody and lupus nephritis in NZM2410 mice. Clin Exp Immunol 2010, 162:362-367.
7. Nowling TK, Fulton JD, Chike-Harris K, Gilkeson G: Ets factors and a newly identified polymorphism regulate Fli1 promoter activity in lymphocytes. Molecular Immunology 2008, 45:1-12.
8. Svensson JL, Chike-Harris K, Arvia MY, Nowling TK: The mouse and human Fli1 genes are similarly regulated by Ets factors in T cells. Genes Immun 2010, 11:161-172.
9. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Dooley MA: Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol 2004, 31:1928-1933.
10. Tan EM, Cohen AS, Fries JF, Mos] AT, McShane DJ, Rothfield NF, Schaller KG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
11. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1272.
12. Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Abo1er T, James JA, Scofield RH, Hafley JB, Gilkeson GS: Autoantibody prevalence and lupus characteristics in a unique African American population. Arthritis Rheum 2008, 58:1237-1247.
13. Sham PC, Curtis D: Monte Carlo tests for association between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995, 59:97-105.
14. Buschiazzo E, Gemmell NJ: The rise, fall and renaissance of microsatellites in eukaryotic genomes. Bioessays 2006, 28:1040-1050.
15. Gebhardt F, Burger H, Brandt B: Modulation of EGFR gene transcription by a polymorphic repetitive sequence—a link between genetics and epigenetics. Int J Biol Markers 2000, 15:105-110.
